Pharmaceutical Management Agency

Future Procurement Opportunity (FPO) – Supply of immune checkpoint inhibitors for the treatment of locally advanced/metastatic non-small cell lung cancer

Pharmac will issue a competitive process for supply of immune checkpoint inhibitors (ICI’s) for the treatment of locally advanced/metastatic non-small cell lung cancer (NSCLC).

The anticipated outcome is a scenario where one or more ICI products would be awarded a period of Principal Supply exclusivity for listing in the Pharmaceutical Schedule, for one or more of the predefined patient groups; patients receiving ICIs for:
- first line 1L monotherapy;
- first line 1L combination therapy;
- second line 2L therapy.

Indicative RFx Release Date: Q3 2022
Project Status: Awaiting approval
Indicative Total Value: $100M +